ASX:CSLBiotechs
How Investors May Respond To CSL (ASX:CSL) After RBC Upgrade Amid Seqirus Spin-Off Pause
RBC Capital recently upgraded CSL to Outperform, arguing that the recent selloff and upcoming February half-year results create a compelling opportunity despite sector headwinds.
The shift in analyst stance comes as investors reassess CSL’s credibility after it cut its fiscal 2026 growth outlook and paused the planned Seqirus vaccines spin-off.
Next, we’ll examine how this upgrade, set against weaker flu vaccine demand and Seqirus uncertainty, shapes CSL’s investment narrative.
We've found...